In recent years, combination therapies for hepatocellular carcinoma (HCC) have been increasingly used with superior treatment responses compared to monotherapies. However, the safety and efficacy of the transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) combinations for HCC patients have not been investigated in the literature. In this study from HIP Investigator Dr. Menggang Yu, the aim was to evaluate the safety and outcomes of TACE after TARE in HCC patients.
All TARE procedures performed on HCC patients at a single institution between January 2008 and November 2016 were retrospectively reviewed. The study found that the addition of TACE to TARE is a safe and effective treatment in unresectable HCC patients and can be considered in select patients with a lack of complete response or disease progression.
Read More